SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high130.00 05/10/16
52 week low71.90 03/05/17
52 week change 4.75 (4.51%)
4 week volume342,510 28/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Silence Strengthens US Patent Estate

RNS Number: 8200L Silence Therapeutics PLC 24 July 2017 Silence strengthens US patent estate 24 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that a further key US patent US 9,695,4...

Presenting at Canaccord Genuity Growth Conference

RNS Number: 8213L Silence Therapeutics PLC 24 July 2017 Silence to present at the Canaccord Genuity 37th Annual Growth Conference 24 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, today an...

CEO Ali Mortazavi appointed Chairman of Ultromics

RNS Number: 0579L Silence Therapeutics PLC 14 July 2017 Silence CEO, Ali Mortazavi, appointed Chairman of Ultromics 14 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its CEO...

Silence Therapeutics notes Alnylam statement

Silence Therapeutics has noted Alnylam Pharmaceutical's 7 July press release, which stated that latter company and Sanofi...

IP update

RNS Number: 5522K Silence Therapeutics PLC 10 July 2017 IP Update 10 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Alnylam Pharmaceutical's press release of July 7, 2017 which stated tha...

Issue of claim in the UK High Courts

RNS Number: 9271J Silence Therapeutics PLC 03 July 2017 Issue of claim in the UK High Courts 3 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today issued a claim in the U...

Change of Adviser

RNS Number: 8420J Silence Therapeutics PLC 03 July 2017 Change of Adviser 3 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces the appointment of Peel Hunt LLP as its Nominated Adv...

Holding(s) in Company

RNS Number: 5940J Silence Therapeutics PLC 29 June 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Silence Therapeutics Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An a...

Fundamental DataMore

EPS-12.1
Dividend yield0 %

Equity Research (SLN)

edison investment research
Silence Therapeutics plc
13/04/2017
Edison Investment Research is terminating coverage on Silence Therapeutics (SLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...

Latest discussion posts More

  • Re: Slow decline.

    Hi, Totally agree and I am not sure why apart from just general lack of interest. The attached might help cheer you up a ...
    27-Apr-2017
    tallyfox
  • Slow decline.

    Feels like death by a thousand cuts at the moment. What's it going to take to reverse this decline?
    27-Apr-2017
    rikid

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.34%
BP24%
BARCLAYS19%
TESCO19%
ROYAL BANK SCOT19%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN